TMCnet News
John C. Ruckdeschel, MD Joins Oncology Analytics' Distinguished Academic Advisory BoardPLANTATION, Fla. --(Business Wire)-- Dr. Ruckdeschel is a leading authority on the diagnosis and management of thoracic malignancies with particular expertise in lung cancer. He received his BSc in Biology from Rensselaer Polytechnic Institute and his MD from Albany Medical College in New York. He trained at Hopkins (Osler Intern), Beth Israel (Resident) and the National Cancer Institute (Fellow). After a decade on the faculty at Albany Medical College he assumed, in 1991, the role of CEO and Director of the Moffitt Cancer Center in Tampa, leading the institution to designation as an NCI Comprehensive Cancer Center in 7 years. In 2001, he assumed the role of CEO and Director of the Karmanos Cancer Institute in Detroit and was able to restore the core grant there. In 2009 he wasrecruited to grow the Nevada Cancer Institute. In 2012 he joined Intermountain Healthcare in Salt Lake City as Medical Director of the Oncology Clinical Program. He is currently CEO of Ruckdeschel Consultants LLC in Las Vegas. Dr. Ruckdeschel's research interests have been primarily in the area of thoracic malignancies where he has chaired numerous national trials and where he served as Thoracic Chair for the Eastern Cooperative Oncology Group and Executive Officer of the Lung Cancer Study Group. He has published extensively with over 160 peer reviewed publications, and is currently involved in efforts to delineate quality measures that can be incorporated into real time management of cancer patients and reduction of cancer burden across populations of high risk patients. About Oncology Analytics, Inc. Oncology Analytics provides chemotherapy decision support services and technology solutions used by more than 4,000 physicians and covering more than 1.5 million members for national health plans. Through clinical research, patented technology and physician-centric customer services, OA ensures treating oncologists have the information they need to deliver the most efficacious, least toxic and most affordable chemotherapy treatments available to their patients. Inc. magazine's 2013 Inc 500|5000 list named OA the 18th fastest growing private companies in the United States health sector.
|
